By Yulia Privolnev, manager, global market access, Decision Resources Group (DRG)
Determining how to evaluate — and whether to reimburse potentially curative one-time cell and gene therapies — is a challenge for payers, before even getting to negotiating prices and figuring out how to pay for them.
The FDA is actively supporting blockchain initiatives for the life sciences industry in the U.S., announcing in June 2019 that it will be sponsoring a pilot for a public, permissioned blockchain to track, trace, and authenticate life sciences materials and products.
By Herman Bozenhardt, Bozenhardt Consulting Services, and Erich Bozenhardt, IPS-Integrated Project Services
This article explores modern facility design principles that make use of the most flexible new technologies and provide a platform to rein in costs, reduce schedules, and deliver products compliantly and within business risk tolerance.